Protalix (PLX) CFO reports updated stock and option holdings

Rhea-AI Filing Summary

Protalix BioTherapeutics, Inc. senior vice president and CFO Gilad Mamlok reports his equity holdings in an amended Form 3. He holds 3,631 shares of common stock directly. He also holds stock options covering 597,990 shares of common stock at an exercise price of $1.45 per share, expiring on July 20, 2035. These options vest in 12 equal quarterly installments from the grant date and can vest faster if there is a corporate transaction or change in control under the company’s Amended and Restated 2006 Stock Incentive Plan.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Mamlok Gilad

Role Sr. VP and CFO

Type	Security	Shares	Price	Value
holding	Stock Option (Right to Buy)	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Stock Option (Right to Buy) — 597,990 shares (Direct, null); Common Stock — 3,631 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Direct common shares: 3,631 shares Underlying option shares: 597,990 shares Option exercise price: $1.45 per share +3 more

6 metrics

Direct common shares 3,631 shares Total shares of common stock held directly after reported holdings

Underlying option shares 597,990 shares Common shares underlying reported stock options held by CFO

Option exercise price $1.45 per share Exercise price of stock options on 597,990 underlying shares

Option expiration July 20, 2035 Expiration date of the reported stock options

Vesting installments 12 quarterly installments Options vest in 12 equal quarterly installments from grant date

Unknown transaction entries 2 entries Filing shows two holding entries with unknown transaction codes

Key Terms

Stock Option (Right to Buy), change in control, Amended and Restated 2006 Stock Incentive Plan, vesting

4 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)" with underlying common stock"

change in control financial

"subject to accelerated vesting upon a corporate transaction or a change in control"

A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.

Amended and Restated 2006 Stock Incentive Plan financial

"as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended"

vesting financial

"shares of common stock underlying the stock options shall vest in 12 equal quarterly installments"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Mamlok Gilad

(Last) (First) (Middle)

CO PROTALIX BIOTHERAPEUTICS, INC.

2 SNUNIT STREET, SCIENCE PARK, P.O. BOX

(Street)

CARMIEL 2161401

(City) (State) (Zip)

ISRAEL

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
08/24/2025

3. Issuer Name and Ticker or Trading Symbol
Protalix BioTherapeutics, Inc. [ PLX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)
08/25/2025

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Sr. VP and CFO

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	3,631	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(1)	07/20/2035	Common Stock	597,990	$1.45	D

Explanation of Responses:

1. The shares of common stock underlying the stock options shall vest in 12 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended.

Remarks:

On August 25, 2025, the reporting person filed a Form 3 which inadvertently omitted the reporting person's beneficial ownership of 3,631 shares of the issuer's common stock.

	/s/ Gilad Mamlok	04/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does Protalix BioTherapeutics (PLX) CFO Gilad Mamlok report in this amended Form 3?

He reports his current equity holdings in Protalix BioTherapeutics. This includes directly held common shares and a large stock option position that can convert into common stock under specified terms and vesting conditions detailed in the company’s stock incentive plan.

How many Protalix BioTherapeutics (PLX) common shares does the CFO hold directly?

Gilad Mamlok holds 3,631 shares of Protalix common stock directly. This figure represents his reported direct ownership as of the Form 3/A filing date, separate from any additional shares that could be obtained through exercisable stock options granted as part of his compensation.

What stock options in Protalix BioTherapeutics (PLX) does the CFO report holding?

He reports stock options labeled as a “Stock Option (Right to Buy)” tied to 597,990 underlying common shares. These options give him the right to purchase Protalix common stock at a fixed exercise price, subject to vesting over time and the stated expiration date.

What is the exercise price and expiration date of the CFO’s Protalix (PLX) stock options?

The stock options have an exercise price of $1.45 per share and expire on July 20, 2035. This means he can buy up to 597,990 shares at $1.45 each before that expiration date, assuming the options vest and remain outstanding.

How do the Protalix (PLX) CFO’s stock options vest according to the filing?

The options vest in 12 equal quarterly installments starting on the grant date. This schedule gradually makes portions of the 597,990-share option exercisable, aligning the CFO’s long-term incentives with the company’s ongoing performance over multiple quarters.

What happens to the Protalix (PLX) CFO’s options if there is a change in control?

The filing states the options are subject to accelerated vesting upon a corporate transaction or change in control. Under the company’s Amended and Restated 2006 Stock Incentive Plan, such an event can cause unvested portions of the options to vest more quickly than the standard quarterly schedule.